Government figures put the Ebola death toll in the Democratic Republic of Congo at 2,325, the highest in the country’s history. That surpasses the previous national record of 2,299 during the 2018 to 2020 epidemic. At that point, authorities had recorded 4,945 confirmed cases and 101 new infections in the preceding 24 hours.
Those figures were an earlier snapshot of an outbreak that continued to expand. The World Health Organization (WHO) reported 9,637 confirmed cases and 4,646 deaths as of 19 October 2026, with transmission in 66 health zones across eight provinces. Wapinda Health Zone in Nord-Ubangi Province was among the areas newly affected. On 20 October, WHO reported 9,704 confirmed cases and 4,687 deaths, a crude case-fatality ratio of 48.3%. A United Nations briefing on 23 October put the toll at 9,765 cases and 4,727 deaths and said approximately 30,000 contacts were being monitored daily. WHO’s Ebola Incident Manager in the DRC, Dr Catherine Smallwood, said that “nearly six months into the outbreak, 9,765 confirmed Ebola cases and 4,727 deaths had been recorded.”
The outbreak began in January but was officially declared in May, information from the Congolese Institute of Public Health. The virus is Bundibugyo ebolavirus, a species distinct from the Zaire ebolavirus responsible for earlier outbreaks targeted by licensed vaccines and treatments. By late July, case numbers had already set a new national record. Continued spread across provinces is making response coordination more demanding, especially for surveillance and contact tracing.
WHO declared a Public Health Emergency of International Concern on 17 May 2026. On 5 June, WHO and the Africa Centres for Disease Control and Prevention launched a joint continental preparedness and response plan. The European Centre for Disease Prevention and Control says there are no licensed vaccines or specific therapeutics for Bundibugyo virus disease. Candidates under investigation include Oxford’s ChAdOx1-BDBV and a Moderna mRNA candidate. Research also covers rVSV-based candidates developed by IAVI and PHV, as well as Minapharm’s MVA-CR19. WHO has recommended that the licensed rVSV-ZEBOV vaccine, marketed as Ervebo, be used primarily under a research protocol to assess possible cross-protection and clinical efficacy.
The case-fatality rate cited in government data rose from around 20% in early June to 46% in a later update; WHO reported a crude rate of 48.3% as of 20 October. A high crude case-fatality ratio describes deaths as a proportion of confirmed cases and does not, by itself, establish that the virus has become more lethal. Experts caution that the figure can also reflect delays in detecting cases and gaps in surveillance, as well as barriers to medical care. Ebola spreads through direct contact with the bodily fluids of infected people, living or deceased. It can cause symptoms including fever and vomiting, along with severe bleeding.
The outbreak is placing additional pressure on communities already affected by conflict, displacement and food insecurity. In Haut-Uélé Province, WHO reported 421 confirmed cases and 180 deaths as of 19 October, with seven of the province’s 13 health zones affected. Population movement has raised cross-border concerns, particularly near South Sudan. The DRC and South Sudan have strengthened surveillance and coordination, including alert detection and contact tracing. Their work also covers laboratory testing, health-worker training and preparation of treatment facilities. WHO has supported preparedness in neighboring countries. The humanitarian response includes treatment facilities and food assistance, along with transport and logistics support for hard-to-reach areas.
The rapid progression and high mortality have drawn international attention to the DRC. Other recent health emergencies in Africa, including Moroccan authorities’ removal of migrant camps near Melilla, have also tested local health and security systems, as described in coverage of the Gurugú Mountain operation.
Ebola outbreaks have repeatedly challenged public-health infrastructure in Central and West Africa. The Bundibugyo virus was first identified in Uganda in 2007 and is less well studied than the Zaire species, which has been the target of most vaccine development. With no licensed Bundibugyo-specific medical countermeasures, containment depends on detecting cases early and isolating patients, alongside supportive care. Teams also rely on infection prevention and control, as well as sustained contact tracing. The outbreak has made international cooperation and regional preparedness basic to the response.
